&Partners’s Guardant Health GH Stock Holding History

&Partners’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$353K	Sell	2,348 -877	-27%	-$95.4K	﹤0.01%	2040
2026 Q1	$297K	Buy	+3,225	New	+$324K	﹤0.01%	2000

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

&Partners's GH Position: Q2 2026 in Review

&Partners reduced its Guardant Health (GH) stake by 27% in Q2 2026, selling an estimated $95.4K and leaving 2,348 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #2040.

&Partners first reported a position in GH in Q1 2026 and has held it in 2 quarters since. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

&Partners held 2,348 shares of Guardant Health worth $353K as of Q2 2026.
&Partners sold 877 Guardant Health shares in Q2 2026, an estimated $95.4K.
Guardant Health made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2040 holding.
&Partners first reported a position in Guardant Health in Q1 2026 and has held it in 2 quarters since.
597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.